Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 491-495

  Oshita, Fumihiro ^a   Kameda, Yoichi ^a   Nishio, Kazuto ^b   Tanaka, Gaku ^a   Yamada, Kouzo ^a   Nomura, Ikuo ^a   Nakayama, Haruhiko ^a   Noda, Kazumasa ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cdk; Cisplatin; Immunostaining

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; DRUG ANTAGONISM; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0034182738     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.491     Document Type: Article

References (25)

1. Shinkai T, Eguchi K, Sasaki Y, et al: A prognostic-factor risk index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30: 1-6, 1992.
2. Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD and Saijo N: Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res 81: 527-535, 1990.
3. Kasahara K, Fujiwara Y, Nishio K, et al: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237-3242, 1991.
4. Ohmori T, Morikage T, Sugimoto Y, et al: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J Cancer Res 84: 83-92, 1993.
5. Oshita F, Yamamoto N, Fukuda M, et al: Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. Cancer Res 55: 2334-2337, 1995.
6. Oshita F and Saijo N: Use of the polymerase chain reaction to measure variations in gene-specific repair of cisplatin-induced DNA damage between cisplatin-sensitive and -resistant lung cancer cell lines, and in mononuclear cells of lung cancer patients. Cell Pharmacol 2: 205-209, 1995.
7. MacLachlan TK, Sang N and Giordano A: Cyclin, cyclin-dependent kinases and Cdk inhibitors: implication in cell cycle control and cancer. Crit Rev Eukaryotic Gene Expression 5: 127-156, 1995.
8. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M and Roberts JM: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228, 1991.
9. Polyak K, Lee MH, Erdjement-Bromage H, Koff A, Roberts JM, Tempst P and Massague J: Cloning of p27/kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 79: 59-66, 1994.
10. Toyoshima T and Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
11. Nourse J, Firpo E, Flanagan M, et al: Interleukin-2-mediated elimination of p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994.
12. Hengst L and Reed S: Translation control of p27kip1 accumulation during the cell cycle. Science 271: 1861-1864, 1996.
13. Pagano M, Beer-Romero P, Glass S, Tam SW, Theodoras A, Rolfe M and Draetta G: Targeting ubiquitin-mediated degradation for proliferation inhibitors. In: Cancer Genes. Plenum Publishing Corp, New York, pp255-268, 1997.
14. Pagano M, Tam SW, Theodoras A, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
15. Porter PL, Malone KE, Heagerty PJ, et al: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997.
16. Catzavelos C, Bhattacharya N, Ung YC, et al: Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997.
17. Loda M, Cukor B, Tam SW, et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat Med 3: 231-234, 1997.
18. Esposito V, Baldi A, Luca AD, et al: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997.
19. Croix BT, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM and Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anticancer agents. Nat Med 2: 1204-1210, 1996.
20. World Health Organization: WHO Hand Book for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, 1979.
21. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 27: 4730-4734, 1988.
22. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211-1214, 1995.
23. Kawamata N, Morosetti R and Miller CW, et al: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55: 2266-2269, 1995.
24. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW and Koeffler HP: p27/Kip1 mutation found in breast cancer. Cancer Res 56: 2400-2404, 1996.
25. Naruke T, Goya T, Tsuchiya R and Suemasu K: Prognosis and survival in resected lung cancer, based on the new international staging system. J Thoracic Cardiovasc Surg 96: 440-447, 1988.